Current neuro-ophthalmic therapies

Neurologic Clinics

Volumn 19, Issue 1, 2001, Pages 145-172

  Movsas, Tammy Z ^a   Liu, Grant T ^a   Galetta, Steven L ^a   Balcer, Laura J ^a   Volpe, Nicholas J ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; AZATHIOPRINE; BARBITURIC ACID DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; CORTICOSTEROID; EDROPHONIUM; GABAPENTIN; ISONIAZID; MEMANTINE; NEOSTIGMINE; PREDNISONE;

ABDUCENS NERVE DISEASE; BRAIN PSEUDOTUMOR; DIPLOPIA; INTRACRANIAL HYPERTENSION; MYASTHENIA GRAVIS; NEUROOPHTHALMOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; NYSTAGMUS; OPHTHALMOPLEGIA; OPHTHALMOSCOPY; OPTIC NERVE DISEASE; OSCILLOPSIA; PRIORITY JOURNAL; QUALITY OF LIFE; RACE DIFFERENCE; REVIEW; STEROID THERAPY; SUPERIOR OBLIQUE MUSCLE; TEMPORAL ARTERITIS; THYROID DISEASE;

EID: 0035015408     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8619(05)70010-4     Document Type: Article

References (150)

1. Intravenous immunoglobulin treatment in multiple sclerosis
2. Visual prognosis in giant cell arteritis
3. Thresholds in cerebral ischemia: The ischemic penumbra
4. Surgical treatment in nystagmus
5. Medical treatments for abnormal eye movements: Pharmacological, optical and immunological strategies
6. Gabapentin as treatment for nystagmus
7. A double-blind controlled study of gabapentin and baclofen as treatment for acquired nystagmus
8. Idiopathic intracranial hypertension: Relation of age and obesity in children
9. Muscarinic antagonists in the treatment of acquired pendular and downbeat nystagmus: A double-blind, randomized trial of three intravenous drugs
10. The optic neuritis treatment trials
11. Brain magnetic resonance imaging in acute optic neuritis: Experience of the optic neuritis study group
12. The course of visual recovery after optic neuritis: Experience of the optic neuritis treatment trial
13. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis
14. Place of radiotherapy in the treatment of Graves' orbitopathy
15. Giant cell arteritis: The need for prolonged treatment
16. Scopalamine induces an increase in muscarinic receptor level in rat hippocampus
17. An alternate-day corticosteroid regimen in maintenance therapy of giant cell arteritis
18. Glucocorticoid-mediated repression of cytokine gene transcription in human arteritis-SCID chimeras
19. Binocular vertical diplopia
20. Elevated intracranial pressure and pseudotumor cerebri
21. Protracted post surgical blindness with visual recovery following optic nerve sheath fenestration
22. Optic nerve sheath decompression for pseudo-tumor cerebri
23. Surgical treatment of supranuclear and internuclear ocular motility disorders
24. Botulinum toxin chemodenervation of the inferior oblique muscle for chronic and acute IV nerve palsies
25. Lumboperitoneal shunting for pseudohnnor cerebri
26. Drug therapy of nystagmus and saccadic intrusions: Vestibular dysfunction and its therapy
27. Comment on botulinum toxin chemodenervation of the inferior oblique muscle for chronic and acute IV nerve palsies
28. Medical treatment of nystagmus and ocular motor disorders
29. The role of radiation therapy in Graves' ophthalmopathy
30. Idiopathic intracranial hypertension in prepubertal pediatric patients: Characteristics, treatment and outcome
31. Combined radiotherapy and medical immunosuppression in the management of thyroid eye disease
32. Visual symptoms after optic neuritis: Results from the optic neuritis treatment trial
33. Temporal arteritis: Improvement in visual prognosis and management with repeat biopsies
34. Results of optic nerve fenestration for pseudotumor cerebri: The lateral orbitotomy approach
35. The rational management of idiopathic intracranial hypertension
36. Progressive visual loss from giant cell arteritis despite high dose intravenous methylprednisolone
37. The use of clonazepam in the treatment of nystagmus-induced oscillopsi
38. Neurochemistry of the central vestibular pathways
39. Polymyalgia rheumatica and temporal arteritis: A retrospective analysis of prognostic features and different corticosteroid regimens
40. Improving visual acuity in congenital nystagmus
41. Contact lenses and congenital nystagmus
42. The effects of baclofen and cholinergic drugs on upbeat and downbeat nystagmus
43. Medical progress: Myasthenia gravis
44. Lumboperitoneal shunt for the treatment of pseudotumor cerebri
45. Molecular mechanisms of regulation of neuronal muscarinic receptor sensitivity
46. For the Austrian Immunoglobulin in Multiple Sclerosis Study Group: Randomized placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis
47. Squints and diplopia seen after brain damage
48. Isolated fourth nerve palsy from midbrain hemorrhage
49. Giant cell arteritis with unusual flow-related neuro-ophthalmologic manifestations
50. Diagnostic tests in neuro-ophthalmology
51. The novel anticonvulsant drug, gabapentin (neurontin) binds to the alpha2delta subunit of a calcium channel
52. Current concepts in giant cell (temporal) arteritis
53. Optic nerve sheath fenestration for pseudotumor cerebri
54. An ice test for the diagnosis of myasthenia gravis
55. Permanent visual loss and cerebrovascular accidents in giant cell arteritis
56. Nystagmus
57. Congenital periodic alternating nystagmus
58. Prognosis in giant cell arteritis
59. Jerk-waveform see-saw nystagmus due to unilateral meso-diencephalic lesion
60. Anterior ischemic optic neuropathy: Differentiation of arteritic from nonarteritic type and its management
61. Giant cell arteritis: Validity and reliability of various diagnostic criteria
62. Ocular manifestations of giant cell arteritis
63. Myasthenia gravis: Clinical features, pathogenesis, evaluation and medical management
64. Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: Comparison in a prospective study
65. Interferon on beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial
66. The search for the cause of idiopathic intracranial hypertension: A preliminary case-control study
67. Treatment of nystagmus by acupuncture
68. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis
69. Correlation of clinical, magnetic resonance imaging and cerebrospinal fluid findings in optic neuritis
70. Intramuscular interferon Beta-1a therapy initiated during a first demyelinating event in multiple sclerosis
71. The role of weight loss and acetazolamide in the treatment of idiopathic intracranial hypertension (pseudotumor cerebri)
72. Effects of intravenous methylprednisolone on outcome in MRI-based prognostic subgroups in acute optic neuritis
73. A nystagmus operation
74. 12 analog, against glutamate-induced neurotoxicity in retinal cell cultures
75. Therapy of Graves' ophthalmopathy with intravenous high-dose steroid followed by orbital irradiation
76. Visual performance in giant cell arteritis (temporal arteritis) after 1 year of therapy
77. Comment on visual symptoms after optic neuritis
78. Methotrexate use in systemic vasculitis
79. Acute visual loss and other disorders of the eyes
80. Giant cell arteritis and intravenous methylprednisolone
81. Optic nerve sheath decompression in pediatric pseudotumor cerebri
82. Nonpharmacological treatment of nystagmus
83. Effect of anticholinergic agents upon acquired nystagmus: A double-blind study of trihexyphenidyl and trihexethyl chloride
84. Treatment of strabismus and nystagmus with botulinum toxin type A: An evaluation of effects and complications
85. Pediatric pseudotumor cerebri (idiopathic intracranial hypertension)
86. High dose methylprednisolone and acetazolamide for visual loss in pseudotumor cerebri
87. Visual morbidity in giant cell arteritis: Clinical characteristics and prognosis for vision
88. Pseudotumor cerebri and its medical treatment
89. Clinical and MRI correlates in 27 patients with acquired pendular nystagmus
90. Gabapentin increases aminooxyacetic acid-induced GABA accumulation in several regions of rat brain
91. Risk factors for developing multiple sclerosis after childhood optic neuritis
92. Restricted dose and duration of corticosteroid treatment in polymyalgia rheumatica and temporal arteritis
93. Oculomotor motion disorders: Current imaging of cranial nerves 3, 4 and 6
94. GD-DTPA enhancement of the cisternal portion of the oculomotor nerve on MR imaging
95. Acquired myasthenia gravis
96. Long-term survival of patients with giant cell arteritis in the American College of Rheumatology giant cell arteritis classification criteria cohort
97. Hereditary cerebellar degeneration with downbeat nystagmus: A case and its treatment
98. Magnetic resonance imaging of the optic nerve in optic neuritis
99. Central nervous system vasculitis
100. Acquired pendular nystagmus suppressed by alcohol
101. A prospective study of thymectomy and serum acetylcholine receptor antibodies in myasthenia gravis
102. The clinical profile of optic neuritis: Experience of the optic neuritis treatment trial
103. The 5 year risk of multiple sclerosis after optic neuritis
104. Visual function 5 years after optic neuritis
105. Osteoporosis in steroid-treated patients with polymyalgia rheumatica and temporal arteritis: What is the magnitude and rate after 1 year
106. Intermittent downbeat nystagmus and oxcillopsia reversed by suboccipital craniectomy
107. Optic neuritis in African-Americans
108. Randomized double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy
109. Idiopathic intracranial hypertension (pseudotumor cerebri): Descriptive epidemiology in Rochester, Minn, 1976-1990
110. Epidemiology of idiopathic intracranial hypertension: A prospective and case-control study
111. Discussion of congenital periodic alternating nystagmus
112. Treatment of acquired nystagmus with botulinum neurotoxin A
113. Risk of developing multiple sclerosis after uncomplicated optic neuritis: A long-term prospective study
114. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis
115. A prism is a useful tool in the treatment of vertical diplopia
116. Treatment of temporal arteritis with ocular involvement
117. The use of botulinum toxin for treatment of acquired nystagmus and oscillopsia
118. Iatrogenic morbidity accompanying suppression of temporal arteritis by adrenal corticosteroids
119. On the utility of CD8 level assessment in the diagnosis of polymyalgia rheumatica/giant cell arteritis
120. Color duplex ultrasonography in the diagnosis of temporal arteritis
121. Idiopathic intracranial hypertension in children and adolescents
122. Transsternal thymectomy for myasthenia gravis
123. A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis
124. Modified optic nerve sheath decompression provides long term visual improvement for pseudotumor cerebr
125. The effects of afferent stimulation on congenital nystagmus foveation periods
126. Central neurogenic hyperventilation in an awake patient with a pontine glioma
127. Neurogenic diplopia: Paralysis of cranial nerves III, IV, and VI
128. Arnold-Chiari malformation: Improvement in eye movements after surgical treatment
129. Long-term effectiveness of optic nerve sheath decompression for pseudotumor cerebri
130. Mechanisms of high-dose intravenous immunoglobulins in demyelinating disease
131. Effects of gabapentin on pendular ocular oscillations
132. A pilot study of gabapentin as treatment for acquired nystagmus
133. Drug therapy for acquired pendular nystagmus in multiple sclerosis
134. Increased intra-abdominal pressure and cardiac filling pressure in obesity-associated pseudotumor cerebri
135. High-dose intravenous steroid pulse therapy in thyroid-associated ophthalmopathy
136. Clinical experience of radiation therapy for Graves' ophthalmopathy
137. Atypical visual loss in giant cell arteritis
138. Successful treatment of acquired pendular elliptical nystagmus in multiple sclerosis with isoniazid and base out prisms
139. Contrast sensitivity and other vision tests in the optic neuritis treatment trial
140. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?
141. Remitting sixth nerve palsy in skull base tumors
142. Large rectus muscle recession for treatment of congenital nystagmus
143. Multicenter clinical trial for evaluating methylprednisone pulse treatment of idiopathic optic neuritis in Japan
144. Baseline features of idiopathic optic neuritis as determined by a multicenter treatment trial in Japan
145. Idiopathic intracranial hypertension: A prospective study of 50 patients
146. Correlation of the typographical arrangement and the functional pattern of tissue-infiltrating macrophages in giant cell arteritis
147. Treatment of corticosteroid-resistant giant cell arteritis
148. Refinement of an optical device that stabilized vision in patients with nystagmus
149. Video-assisted thorascopic thymectomy for myasthenia gravis